Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Circulation|June 3, 2009
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosisMartin Unverdorben, Christian Vallbracht, Bodo Cremers, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 30, 2014
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR studyMartin Unverdorben, Christian Vallbracht, Bodo Cremers, et al.
The American Journal of Cardiology|September 23, 2023
Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial FibrillationMasanori Yamamoto, Kentaro Hayashida, Christian Hengstenberg, et al.
Journal of Arrhythmia|January 16, 2025
Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registryChun-Chieh Wang, Cheng-I Cheng, Kwo-Chang Ueng, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 27, 2011
Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitusRosli Mohd Ali, Ralf Degenhardt, Robaayah Zambahari, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Major Bleeding Risk Assessment With Atrial Fibrillation Post-TAVR: The HARHP Score Results From ENVISAGE-TAVI AFGeorge D Dangas, Martin Unverdorben, Christian Hengstenberg, et al.
Clinical Cardiology|October 26, 2019
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and designRaffaele De Caterina, Giancarlo Agnelli, Petra Laeis, et al.
JACC. Advances|June 28, 2024
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVRRoxana Mehran, Alessandro Spirito, James Jin, et al.
Frontiers in Pharmacology|February 9, 2026
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China studyXueyuan Guo, Juan Du, Yuehui Yin, et al.
Scientific Reports|February 2, 2024
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registryXueyuan Guo, Juan Du, Yang Yang, et al.
Pageof 8